A real-world study to evaluate the efficacy, tolerability, and tolerability of silver-containing dressings based on lipid hydrogel technology in the treatment of superficial partial-thickness burns of the skin

开始日期2025-01-01

申办/合作机构

海军军医大学第一附属医院

NCT06629558

/ RecruitingN/AIIT

Efficacy and Safety of 0.5% w/v Nano- Silver Nitrate Versus Silver Nitrate Solution for Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema: Prospective Interventional Randomized Controlled Clinical Trial

Emphysema is a progressive phenotype of chronic Obstructive Pulmonary Disease (COPD), poses a significant global health burden characterized by irreversible lung parenchymal destruction and airspace enlargement.
In recent years, bronchoscopic lung volume reduction (BLVR) has considerable interest as a minimally invasive approach to reducing hyperinflation and improving lung function in patients with emphysema.
BLVR techniques aim to achieve lung volume reduction by occluding or ablating emphysematous lung tissue through endobronchial delivery of various agents. Many techniques are available for BLVR as coil, endo-bronchial valve, and biological as thrombin, autologous blood and chemicals as silver nitrate solution.

开始日期2024-10-01

申办/合作机构

Mansoura University Hospital

CTRI/2024/06/068709

/ Not yet recruitingN/AIIT

Indirect Pulp Treatment In Young Permanent Molars: 38% Silver Diamine Fluoride (SDF) with and without light cure- A Clinical Control Trial - NIL

开始日期2024-06-22

申办/合作机构-

100 项与硝酸銀相关的临床结果

登录后查看更多信息

100 项与硝酸銀相关的转化医学

登录后查看更多信息

100 项与硝酸銀相关的专利（医药）

登录后查看更多信息

4,164

项与硝酸銀相关的文献（医药）

2025-12-31·Journal of the International Society of Sports Nutrition

Investigation of the effect of nitrate and L-arginine intake on aerobic, anaerobic performance, balance, agility, and recovery in elite taekwondo athletes

Article

作者: Buzdağlı, Yusuf ; Savaş, Adem ; Kavcı, Zafer ; Uçar, Halil ; Ozan, Murat

BACKGROUNDTaekwondo is a complex martial art that requires speed, balance, agility, and endurance. This study aims to examine the effects of nitrate and L-arginine supplementation on acute aerobic and anaerobic performance, balance, agility, and recovery in elite taekwondo athletes.METHODThis study was conducted as a double-blind, randomized, crossover study with the participation of 15 experienced taekwondo athletes aged 19.06 ± 0.96 years and 8.93 ± 1.27 years of training experience. Participants visited the laboratory a total of nine times, including a practice session and anthropometric measurements. These visits consisted of eight experimental sessions conducted at 72-hour intervals. The experimental sessions were conducted with nitrate, L-arginine, and a combination of both supplements (NIT*L-ARG) and placebo. Nitrate supplementation was provided by homogenizing fresh spinach (837.40 mg/kg), while L-ARG was given as a single dose of 6 g in powder form three hours before exercise.RESULTSNIT*L-ARG supplementation significantly improved the anaerobic performance of athletes in Wingate peak power and peak power (w/kg) compared to placebo and in mean power compared to NIT, L-ARG, and PLA. In addition, NIT*L-ARG supplementation significantly improved blood lactate levels and agility performance immediately after Wingate and Shuttle run tests.CONCLUSIONThe combined intake of NIT*L-ARG was found to be effective in improving aerobic, anaerobic, and agility performances as well as fatigue levels of athletes. It was determined that taking NIT and L-ARG supplements alone contributed to the improvement of improving athletes' performance in Wingate mean power values and subsequent fatigue level compared to PLA.

2025-03-01·Journal of Orthopaedics

Comparative effectiveness of silver-coated implants in periprosthetic infection prevention: A systematic review and meta-analysis

Review

作者: Okay, Erhan ; Ozkan, Korhan ; Kanay, Enes ; Bulut, Halil Ibrahim ; Batibay, Sefa Giray

IntroductionDespite the implementation of numerous preventive measures in recent years, the persistent challenge of periprosthetic infections remains. Among the various strategies, metallic modification of implants, particularly with silver, has emerged as a promising avenue. Silver's antimicrobial properties, coupled with its low human toxicity, render it an appealing option. However, ongoing debate surrounds its comparative efficacy in infection prevention when contrasted with titanium-coated prostheses.MethodsThe PubMed database was systematically searched up to March 2024. Studies in English that met predetermined inclusion/exclusion criteria and utilized "Megaprosthesis AND infection" and " silver-coated AND infection " as key terms were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guided the article selection process.ResultsFrom a pool of 1892 potential papers after literature screening, 11 studies with a total of 1419 patients were meticulously selected for analysis. Among these patients, 638 were treated with silver-coated implants, while 781 received titanium-coated implants, resulting in 166 recorded cases of infection. Remarkably, the infection rate stood at 9.2 % for the silver-coated group, contrasting with 13.4 % for the titanium-coated group. The subsequent analysis unveiled a notable discrepancy in proportions (P difference = -0.0473, 95 % CI: -0.088 to -0.006), signaling a statistically significant decrease in infections within the silver-coated cohort. Furthermore, the I2 statistic, denoting heterogeneity in effect sizes, stood at 21.8 % (95 % CI: 0.0-66.9), indicating a modest degree of variability among the studies. These findings offer compelling insights into the comparative effectiveness of silver-coated implants, suggesting their potential superiority in infection prevention.ConclusionIn conclusion, our systematic review and meta-analysis shed light on the potential of silver-coated implants in mitigating periprosthetic infections. Despite the persistent challenge posed by such infections, our findings suggest a statistically significant decrease in infection rates among patients treated with silver-coated implants compared to those with titanium-coated ones.

2025-03-01·JPRAS Open

Xeroform gauze versus silver sulfadiazine for mixed-depth pediatric scald injuries: A retrospective study

Article

作者: Klein, Justin D ; Shanti, Christina M ; Alessio-Bilowus, Dominic ; Ridelman, Elika

IntroductionSilver sulfadiazine 1 % cream had historically been the mainstay initial treatment for scald wounds at our institution. However, we transitioned to using closed dressings of only petrolatum-impregnated 3 % bismuth tribromophenate gauze (Xeroform) for all partial-thickness burns. Xeroform adheres to the wound while allowing the exudates to drain and acts as a scaffold for re-epithelialization, after which it falls off without traumatizing the wound bed, theoretically allowing viable tissue to declare itself while requiring less frequent dressing changes.Materials and MethodsA retrospective chart review was conducted of patients aged ≤5 years with mixed-depth scald injuries between the years 1) 2004 and 2008, during which silver sulfadiazine was the standard initial choice and 2) 2015 and 2018, when only Xeroform was used as the standard.ResultsThe study included 347 patients, among whom 200 were treated with silver sulfadiazine and 147 were treated with Xeroform alone. The 2 groups had similar burn sizes and rates of skin grafting (silver group 30/200 [15.0 %] and Xeroform group 20/147 [17.7 %]) However, the Xeroform group showed longer time from injury to grafting (24 vs. 9.9 days, p = 0.002) but showed a significantly smaller mean graft size than the silver group (147 vs. 336 cm², p = 0.027).ConclusionsThese findings suggest that using Xeroform may promote better wound healing than using silver sulfadiazine. In addition, patients with Xeroform can be discharged with their dressings in place for grafting in the outpatient setting, during which time they are in closed dressings without frequent changes and associated discomfort.

项与硝酸銀相关的新闻（医药）

2024-04-16

·PRNewswire

Journal of the American Chemical Society Differentiates EVŌQ Nano's EVQ-218 Nanoparticle as a New Form of Silver; Holds Promise for Widespread Medical Applications

EVQ-218 is the first stable, nonemissive, pure metal nanoparticle on par with NIST standards for ideal materials. The 'clean and green' EVQ-218 nanosilver is free of toxic ion emissions. SALT LAKE CITY, April 16, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries, today announced that the American Chemical Society journal, ACS Omega, published a peer-reviewed study characterizing and differentiating the company's lead asset, EVQ-218, as a new form of silver nanoparticle (AgNP). EVQ-218 meets the highest standards set by the National Institute of Standards and Technology (NIST) while avoiding the limitations and safety risks of other nanosilvers. Continue Reading Engineered by EVŌQ Nano, EVQ-218 is the first and only stable, non-ionic silver nanoparticle (AgNP) for medical applications. The characterization of EVQ-218 is timely as the rise of antimicrobial resistance (AMR) has caused a surge of research into safer, more effective treatments. Prioritized by the World Health Organization as one of the top 10 global public health threats, AMR threatens the effective prevention and treatment of infections.1 "The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs," said Shaun Rothwell, EVŌQ Nano CEO. While silver's antibacterial qualities have been known for centuries,2,3 it is widely established that the antimicrobial activity is due to ion emission, which poses toxicity risks for biomedical and consumer product applications.4-7 Realizing Silver's Therapeutic Potential Compared to traditional nanosilvers, EVQ-218 is differentiated due to its characterization and behavior as the first stable, nonemissive, pure silver nanoparticle that is on par with NIST standards for ideal materials, making it a superior candidate for biomedical and consumer product use.8 "Not only does EVQ-218 match NIST's standards for particle size and shape, but it possesses an ultrastable shell structure that completely inhibits ion emission — a first for a pure metal nanoparticle," said Bretni Kennon, Ph.D., principal investigator, EVŌQ Nano. Novel Mechanism of Action EVQ-218's antimicrobial efficacy is rooted in its ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This blocks activation of bacterial mutations that contribute to AMR. In contrast, nanosilvers with ions rupture cell walls, triggering activation of AMR pathways. Multi-Patented Laser Nanofabrication Process EVQ-218 is a high-energy produced silver nanoparticle with a method of manufacture that avoids chemical or biological synthesis. Ablation via a multiple, cross-laser system occurs at temperatures and pressures akin to diamond formation. The patented single-step, high-volume laser process generates stable, pure metal nanoparticles directly into pharmaceutical-grade water.8 The sub-10 nm spherical nanoparticles have an ultrastable shell structure that inhibits the hallmark ion emission that occurs in other nanosilver species.8 The resulting particle size and shape characteristics prevent the need for stabilizing chemistries.8 When factoring in shelf life, EVQ-218 maintains uniform stability for years; traditional nanosilvers degrade within weeks.8 These properties make EVQ-218 an attractive clean and green alternative to traditional nanosilvers.8 Advancing Antimicrobial Solutions With EVQ-218 To address the critical issue of healthcare-associated infections (HAIs), primarily caused by indwelling devices like catheters, EVŌQ Nano is collaborating with leading catheter manufacturers. By infusing EVQ-218 throughout the polymer, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.9 EVŌQ Nano has also received two grants from the Cystic Fibrosis Foundation for the development of an inhaled therapeutic to treat pulmonary bacterial infections. The company had its Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in March and, with the agency's feedback, is confidently advancing toward Phase I clinical trials. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates uniform, sub-10 nm nanoparticles with distinct surface chemistry. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Walsh TR, Gales AC, Laxminarayan R, Dodd PC. Antimicrobial resistance: addressing a global threat to humanity. PLoS Med. 2023 Jul 3;20(7):e1004264. doi: 10.1371/journal.pmed.1004264. PMID: 37399216; PMCID: PMC10317217. Alexander JW. History of the medical use of silver. Surg Infect. 2009;10(3):289. Medici S, Peana M, Nurchi VM, Zoroddu MA. Medical uses of silver—history, myths, and scientific evidence. J Med Chem. 2019;62:5923−5943. Stabryla LM, Johnston KA, Millstone JE, Gilbertson LM. Emerging investigator series: it's not all about the ion: support for particle-specific contributions to silver nanoparticle antimicrobial activity Environ Sci Nano. 2018;5:2047−2068. Kedziora A, Speruda M, Krzyzewska E, Rybka J, Bugla-Ploskonska G. Similarities and differences between silver ions and silver in nanoforms as antibacterial agents. Int J Mol Sci. 2018;19:444. Slavin YN, Asnis J, Häfeli UO, Bach H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology. 2017;15:65. Liao C, Li Y, Tjong SC. Bactericidal and cytotoxic properties of silver nanoparticles. Int J Mol Sci. 2019;20:449. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024;9(7):7891-7903. doi: 10.1021/acsomega.3c07745. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. . SOURCE EVOQ Nano

2024-04-08

·Mass Device

Orthobond wins FDA de novo approval for antibacterial technology that could have vast device applications

The Monmouth Junction, New Jersey-based device developer says it’s the first time the FDA has granted a de novo request for a non-eluting coating designed to actively kill bacteria that could contaminate the surface of a medical device. Orthobond was founded by Princeton University Chemistry Professor Emeritus Jeffrey Schwartz and the late Dr. Gregory Lutz, who was physiatrist-in-chief emeritus at the Hospital for Special Surgery. Lutz died of cancer on March 5, but knew FDA approval was on the horizon. Orthobond CEO David Nichols called the FDA approval a “testament to Gregory’s legacy” in a statement shared with MassDevice. “We are proud to be able to carry it on into this next chapter.” The first application will be Ostaguard-treated SeaSpine Mariner pedicle screws, according to FDA records. Those could be used in patients early next year, Nichols (a former Zimmer Biomet executive) said in an exclusive interview with MassDevice. Orthobond’s proprietary technology is a quaternary ammonium compound coating that’s highly effective in neutralizing the different bacteria responsible for most device-related infections and can be applied to almost any device, he said. Medical Design & Outsourcing: How Orthobond’s antimicrobial coating prevents contamination of medical devices Unlike antibiotic-eluting devices, Ostaguard doesn’t use antibiotics so there’s no risk of creating drug-resistant superbugs. And while antimicrobial materials like silver, palladium and copper can kill bacteria, those toxic metals aren’t biocompatible with human tissue, Nichols said. “Those have been the barriers for decades,” he said. “[Ostaguard] is a brand new category for the FDA. It doesn’t come off the device — it is considered a device — and it actively kills bacteria.” The FDA gave the new category a generic name of “spinal fusion device with quaternary ammonium compound coating,” defined as “a rigid metallic implant device or system comprised of single or multiple components intended to facilitate fusion in skeletally mature patients. The device includes a quaternary ammonium compound coating that is covalently bonded to the device. Where applied, the coating is intended to reduce microbial contamination on the surface of the device prior to implantation. The device does not contain antimicrobial agents that act within or on the body and this device type does not include combination products.” According to an approval letter shared by Ostaguard, the FDA classified the product as a Class II device and established special controls, which Orthobond declined to divulge. While Orthobond said it found no evidence of local or systemic toxicity in sheep, guinea pig and canine testing, the coating technology has not been evaluated in human clinical trials. Orthobond says the technology’s intellectual property is protected through 2037 through three patent fences covering the covalent surface chemistry, antimicrobial layer and analytical processes, including 27 patents and 12 pending applications. Orthobond intends to seek 510(k) clearances for additional orthopedic spinal implant indications before expanding to other fields such as joint reconstruction, oncology, sports medicine, plastic surgery and cardiovascular. “We’re working on a neuromodulation device, there’s a trauma device we’re working on, and we’re going to work on a cochlear implant,” Nichols said. “If you use a cochlear implant and it gets infected, you pretty much lose your hearing. That’s something that they want to solve.” “We’d like to be as broad as possible,” he continued. “… This should be on all devices that get used. There’s no reason why not. If you’re going to sterile package them, why don’t you put an antibacterial on them?” Beyond medtech, Orthobond leaders believe the technology could also have commercial and industrial applications in areas such as automotive, consumer products and textiles. about how Orthobond’s Ostaguard antibacterial technology works and additional potential applications at our sister site, Medical Design & Outsourcing.

上市批准

2024-02-22

·PRNewswire

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 Billion Catheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care. More than 1 million HAIs occur annually in the U.S., causing significant morbidity and mortality. The majority of HAIs are associated with indwelling devices, with catheter-associated urinary tract infections (CAUTIs) representing the most common type.1 Rising antimicrobial resistance has compounded this health threat — as up to one-third of CAUTIs in the U.S. are drug resistant,2 with annual treatment cost exceeding $13 billion.3 "For nearly 30 years, companies have tried to create antimicrobial devices, but the performance never proved effective. Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano. "With its proven ability to resist microbial growth and biofilm formation without triggering antimicrobial resistance, this platform has the potential to significantly impact device-related infections — much like the antibiotic revolution transformed infectious disease treatment a century ago." By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.4 Strong Antimicrobial Efficacy In collaboration with the world's leading catheter manufacturers, extensive lab testing on catheters, luers, and fittings manufactured with EVŌQ Nano's EVQ-218 nanoparticle infused throughout the polymer, demonstrated: Strong antibacterial, antifungal, and antibiofilm efficacy Staphylococcus aureus: 7-8 log reduction Pseudomonas aeruginosa: 6-7.5 log reduction Candida albicans: 5-6.5 log reduction Broad-spectrum activity against 64 bacterial strains tested No degradation of antimicrobial activity; sustained presence for the life of the product Novel Mechanism of Action Existing antimicrobial solutions for medical devices have fallen short. Coatings slough off, degrade over time, and can only be applied to limited materials. While silver is a proven and powerful antimicrobial, current antibacterial catheters externally coated with silver lose efficacy once inserted due to natural sloughing of the material coupled with the short life of silver ions. This combination hinders the antimicrobial activity of current products. EVQ-218 is the first and only non-ionic silver nanoparticle. Extensive studies characterize EVQ-218 as a new form of silver nanoparticle (AgNP), manufactured with EVŌQ Nano's multi-patented nanofabrication process that requires only laser energy, ultrapure water, and pure silver metal.5 Unlike standard silver nanoparticles, EVQ-218 has true "bare" silver surface chemistry, with greater group stability that mitigates the need for added stabilizers.5 The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs. EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This avoids activation of bacterial mutations that contribute to antimicrobial resistance. In contrast, nanoparticles with silver ions rupture cell walls, triggering activation of resistance pathways. By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates nanoparticles that are uniformly sized, surfactant-free, with consistent spherical morphology, and no ion emissions under standard and stressed conditions. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Health Care-Associated Infections. Patient Safety Network. Published September 7, 2019. Accessed November 21, 2023. Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. Res Rep Urol. 2022; Apr 4;14:109-133. doi: 10.2147/RRU.S273663. PMID: 35402319; PMCID: PMC8992741 Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. Content last reviewed November 2017. Accessed January 19, 2024. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024. doi: 10.1021/acsomega.3c07745 Niedermeyer W, inventor; ATTOSTAT Inc., assignee. Method and apparatus for production of uniformly sized nanoparticles. US patent 9,849,512. November 9, 2017. Dimpka CO, Calder A, Gajjar P, Merugu S, Huang W, Britt DW, McLean JE, Johnson WP, Anderson AJ. Interaction of silver nanoparticles with an environmentally beneficial bacterium, Pseudomonas chlororaphis. J. Haz. Mat. 2011; 188:428-435. doi: 10.1016/j.jhazmat.2011.01.118 SOURCE EVŌQ Nano

100 项与硝酸銀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01730	-	D08AL01	DB11080

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疣	澳大利亚	Sutherland Medical Pty Limited	2016-07-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02519738 (CTgov)	临床3期	化脓性肉芽肿	52	Silver Nitrate (Silver Nitrate)	選糧遞獵鹹齋網夢鹽獵(獵蓋繭鑰淵鏇齋鏇積淵) = 夢廠願積構夢鬱網艱憲製鹽窪蓋壓構齋憲壓廠 (範餘衊願醖鑰廠夢遞選, 齋窪積網獵鑰艱夢糧選 ~ 積壓齋艱網觸顧餘簾壓) 更多	-	2022-01-25
				Kenalog (Triamcinolone) (Kenalog (Triamcinolone))	選糧遞獵鹹齋網夢鹽獵(獵蓋繭鑰淵鏇齋鏇積淵) = 壓範餘憲憲窪艱淵願蓋製鹽窪蓋壓構齋憲壓廠 (範餘衊願醖鑰廠夢遞選, 窪鬱願選網願窪網廠憲 ~ 鏇憲艱製鏇襯願簾鹹鑰) 更多
AACR2020	N/A	多形性胶质母细胞瘤	-	Silver nanoparticles	鹹製構範鹹簾顧顧構鹹(繭鹽鹽廠製餘壓蓋餘鹹) = 壓夢築艱繭積糧壓艱顧製廠鹽醖齋夢夢艱鑰襯 (衊壓選願夢鬱鏇鏇艱鏇 )	积极	2020-08-15
				Silver nanoparticles + low-level He-Ne laser	鹹製構範鹹簾顧顧構鹹(繭鹽鹽廠製餘壓蓋餘鹹) = 憲鑰鹽繭繭糧膚壓糧廠製廠鹽醖齋夢夢艱鑰襯 (衊壓選願夢鬱鏇鏇艱鏇 )
ERS2016	N/A	气肿	12	Silver Nitrate solution 0.5%	(醖簾鏇選糧製獵鹹糧衊) = 襯窪範築鬱願夢鑰獵鹽願鑰醖憲鹽鏇願鑰艱齋 (鹹鑰窪製窪衊艱鑰醖築 ) 更多	积极	2016-09-01
ACTRN12609000451202 (Pubmed \| J Burn Care Res)	临床3期	烧伤	89	Silver-Based Burns Dressing	衊觸積觸範鏇製醖壓艱(顧衊構鹹淵鹽襯糧廠積) = 網艱壓糧膚襯顧繭襯鹽憲構獵獵齋顧願構窪積 (艱鏇遞選製壓製艱壓觸 )	-	2016-01-01
				Silver-Based Burns Dressing	衊觸積觸範鏇製醖壓艱(顧衊構鹹淵鹽襯糧廠積) = 繭構獵築鹽夢齋鑰網繭憲構獵獵齋顧願構窪積 (艱鏇遞選製壓製艱壓觸 )
NCT00675922 (Soaks, CTgov)	临床2/3期	烧伤	98	Sulfamylon (Percent Infections:Sulfamylon Site)	膚網願蓋願鑰膚齋選壓(網網夢糧選製艱齋鬱膚) = 願範餘網遞齋艱選醖構簾蓋遞淵網構鏇遞壓鬱 (窪膚憲積鑰夢製齋顧選, 廠艱憲廠鹹醖範夢餘衊 ~ 觸範鏇選廠範衊網鹹觸)	-	2013-01-18
				Silver Nitrate (Percent Infections: Silver Nitrate Site)	膚網願蓋願鑰膚齋選壓(網網夢糧選製艱齋鬱膚) = 壓餘鹽顧艱鏇艱蓋淵觸簾蓋遞淵網構鏇遞壓鬱 (窪膚憲積鑰夢製齋顧選, 齋鑰壓構鹽觸淵糧遞膚 ~ 獵範餘夢壓鏇鹹鹹憲製)